ATHM vs CNK

The deterministic scorecard reveals a mixed financial health with a Piotroski F-Score of 6/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite attractive valuation metrics such as a low P/E of 13.07 and a Price/Book of 0.79, the company faces significant headwinds including negative earnings momentum, declining revenue growth, and a dangerously high payout ratio exceeding 100%. The stock trades below analyst target of $27.71 yet remains in a prolonged downtrend with a 5Y return of -75.8%, signaling deep market skepticism. Strong gross margins and zero debt are offset by deteriorating profitability trends and weak technical posture.

CNK exhibits significant financial fragility, characterized by a mediocre Piotroski F-Score of 4/9 and an alarming Debt/Equity ratio of 7.23. The stock is trading at a massive premium, with a current price of $28.48 far exceeding both the Graham Number ($9.12) and the Intrinsic Value ($7.28). Negative YoY revenue and earnings growth, coupled with bearish insider selling by the CFO and a 0/100 technical trend, suggest a high-risk profile despite optimistic analyst price targets.